Treatment News : Tenofovir May Raise Risk of Kidney Damage, but Effect Tapers Over Time

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » February 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

February 13, 2013

Tenofovir May Raise Risk of Kidney Damage, but Effect Tapers Over Time

The commonly prescribed antiretroviral (ARV) tenofovir raises the risk of kidney dysfunction among people with HIV, but the adverse effect occurs mostly within the first two years after beginning the therapy and then tapers in the years following.  Furthermore, it appears that while tenofovir may increase the risk of renal damage, the actual effect in terms of a rise in cases of kidney disease may prove modest. Following on the heels of other research studies that have identified tenofovir’s adverse effects on the kidneys, Canadian researchers looked to establish the magnitude of the effect; they published their findings in the journal Clinical Infectious Diseases.  

The active ingredient in Viread (tenofovir disoproxil fumarate) and a component of Atripla (efavirenz/emtricitabine/tenofovir), tenofovir is currently prescribed to about half of all people with HIV taking antiretrovirals.

The non-randomized study included 1,043 people with HIV taking tenofovir, who were followed up for 10 years; it examined the loss in what is known as the glomerular filtration rate (eGFR), an indicator of kidney function. Researchers compared the cohort’s eGFR to people with HIV who were exposed to other ARVs.

The study found that tenofovir increased the risk of kidney dysfunction by 63 percent and that the drop in eGFR was weighted toward the first two years. The respective eGFR, measured in mL/min/1.73 m2, for years 1, 2, 3 and 4 was -3.05, -4.05, -2.42 and -3.09.  

The findings are buffered by the study’s size as well as the long follow-up period. However, the researchers were not able to effectively speculate the drop in eGFR beyond year four of exposure to tenofovir.

The study’s authors write, “Our study shows that the association was not of a high magnitude and that the quantified loss in eGFR attributable to [tenofovir] is relatively modest after many years of exposure…. [I]t is highly plausible that [tenofovir] exposure, although associated with reduced kidney function, has no severe adverse effects over the long term for most HIV-positive patients.”

To read the study, click here.

Search: tenofovir, HIV, kidney damage, antiretroviral, ARV, renal, Clinical Infectious Diseases, tenofovir disoproxil fumarate, Viread, Atripla, efavirenz, emtricitabine, glomerular filtration rate, eGFR.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.